How does ibogaine reduce opioid withdrawal?

The leading hypothesis is that ibogaine dampens glutamate overactivity through NMDA antagonism, modulates opioid stress and reward signaling, and changes monoamine tone while noribogaine extends anti-craving effects. Observational reports describe 70–80% withdrawal reduction within hours, but randomized placebo-controlled data are still pending.

Is ibogaine a classic psychedelic?

No. It can produce a long visionary state, but pharmacologically it is broader than classical 5-HT2A psychedelics such as psilocybin or LSD. Its proposed addiction effects involve NMDA, kappa-opioid, sigma-1, serotonin, dopamine, and transporter systems.

How long does ibogaine last?

The acute ibogaine experience commonly lasts 24–36 hours. Noribogaine, its active metabolite, can persist for days and may help explain the sustained anti-craving and mood effects reported after the acute phase.

What is noribogaine and why does it matter?

Noribogaine is ibogaine’s main active metabolite. It acts partly as a serotonin reuptake inhibitor and kappa-opioid modulator, extending pharmacologic effects after the initial ibogaine session. In 2026, noribogaine HCl entered FDA-cleared Phase 1 study for alcohol use disorder.

Does ibogaine cure addiction?

No responsible source should call it a cure. Ibogaine may interrupt withdrawal and drug-seeking circuits, but durability depends on medical selection, integration therapy, continuing addiction care, psychiatric support, and environment.

What are the biggest ibogaine safety risks?

The major acute concern is cardiac risk, especially QTc prolongation through hERG-channel effects, medication interactions, electrolyte abnormalities, and pre-existing heart disease. Clinical screening and continuous monitoring are essential.

Is ibogaine legal in the United States in 2026?

Ibogaine itself remains Schedule I federally. However, state-funded research programs in Texas and Arizona and FDA-cleared noribogaine research have expanded regulated pathways for study. Access outside trials remains legally constrained.

Can ibogaine help PTSD or TBI?

Early human and translational data are promising but not definitive. A 2024 Stanford Nature Medicine study in 30 veterans reported large reductions in PTSD, depression, and cognitive impairment after ibogaine treatment; controlled trials are needed.

Who should not use ibogaine?

People with long-QT risk, significant cardiac disease, uncontrolled psychosis or mania risk, pregnancy, severe hepatic instability, dangerous medication interactions, or lack of clinical monitoring should not pursue ibogaine outside regulated medical research.

About | Iboganism

About

Iboganism is an independent information resource on ibogaine for people researching ibogaine, focused on evidence, safety, legality and practical questions about ibogaine. This page explains who we are, how we work, and how we handle sources and independence.

Our editorial services & research notes Visit the site hub

Policy and science converging: state-funded ibogaine research visual

Who we are and why this resource exists

Purpose and mission

Iboganism exists to serve a single audience: people researching ibogaine. Our mission statement is intentionally narrow — we provide evidence-first, plainspoken summaries of the safety, legality, mechanisms, and practical questions surrounding ibogaine so readers can evaluate risks and the evolving clinical landscape.

We are independent: we do not provide treatment, referrals, or clinical services. Our editorial focus is explanatory and evidence-driven, rather than promotional or clinical. For readers who want context on how this content sits alongside treatment options, our services overview explains how we classify clinical trials, observational reports, and policy documents used in our reviews.

Editorial approach

How we source and vet information

We combine systematic literature review, registry checks, and primary-source policy documents to form summaries. That includes searching clinical trial registries, peer-reviewed journals, regulatory notices, and public records from official agencies before flagging an item as "evidence". For claims about safety and legality we consult authoritative sources such as the U.S. Drug Enforcement Administration (DEA) scheduling information and federal policy updates; for methodology and neurobiology we reference recognized academic summaries like the relevant Wikipedia overview and university resources when those pages provide stable, cited syntheses (Wikipedia: Ibogaine).

We also rely on institutional documents to corroborate funding and programmatic claims; for example, when describing state-funded trials we cross-check university press releases and state legislative texts or summaries (readers may contrast our coverage with public university announcements and program pages such as those published by Texas public universities).

Editorial principles

Our editorial principles

Independence

We publish without financial ties to clinics, manufacturers, or promoters of ibogaine treatment.

Evidence-first

We prioritise peer-reviewed data, registered trials, and official regulatory notices over anecdote.

Plain language

We translate technical findings to audience-appropriate summaries without overstating certainty.

What we cover

Scope and organization

Content is organized into topic-driven hubs: mechanism and circuit summaries, safety and drug–interaction notes, evidence reviews and trial trackers, and practical risk considerations. For readers who navigate from topical pages, we maintain cross-links so related material is discoverable in context: for example, when a policy or trial note mentions active clinical programs we place inline references back to the site hub at Iboganism’s main index to preserve narrative continuity.

We also keep an updatable list of active research and state programs as part of our evidence-tracking; where appropriate we reference university trial pages and registry entries rather than secondary reporting. When discussing patient-facing access options we point readers to reputable program descriptions rather than treatment endorsements — our role is explanatory, not clinical.

Vetting and updates

Each substantive page carries a short editorial note describing the review cycle and the last update date. Major shifts in regulatory status or pivotal trial outcomes trigger a full review and flagged summary. To support transparency, we include direct inline links to primary sources within articles; for claims about clinical outcomes we cite trial registry entries or peer-reviewed publications rather than press summaries. We use trusted external references such as university clinical pages and foundational government statistics to contextualize policy and risk (see an example summary at CDC for mortality context).

Who this is for

Audience and use cases

Iboganism is aimed at informed citizens, clinicians seeking concise overviews, researchers tracking trials, and people considering whether to pursue experimental or licensed pathways. We intentionally avoid clinical instructions; if you are evaluating care options, consult licensed professionals and verified program pages rather than relying on our summaries alone. For readers seeking operational guidance or program evaluation resources we provide editorial notes and links to institutional trial pages and public university program announcements as context — for example, some state-funded programs now publish public notices on university sites that clarify protocol and oversight.

For practical local options and clinic listings we do not maintain a referral directory; instead, our services pages explain how we classify evidence and how readers should interpret clinic-reported outcomes.

Independent by design

Disclosure & limits

Iboganism is an independent information resource. It is not a clinic, medical provider, or licensed treatment center, and its content is not medical or legal advice. We do not offer diagnosis, treatment, or referrals.

Where material touches on active trials, scheduling status, or state programs we cite official university pages, registry entries, and government notices. For readers who want to cross-check scheduling and legal classification, official DEA and federal agency pages remain the definitive sources (DEA).

Editorial commitments

Independence: no promotional ties to clinics or product makers.
Transparency: inline sourcing and update notes on substantive pages.
Conservative interpretation: we avoid overstating preliminary findings.
User-first structure: material organized for people researching ibogaine.

If you arrived here from external program pages or news coverage, you may find our contextual overview helpful — readers frequently navigate from university press releases or clinic reports to compare claims; when doing so we recommend checking registry entries and institutional trial pages directly (for example, public trial registries at ClinicalTrials.gov).

Back to Iboganism hub